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approved therapies for its beneﬁ ciaries far advancing the national health basket. 
GOALS: The current work describes trends in MHS medication use and expenditures
over the last decade. OUTCOMES ITEMS USED IN THE DECISION: Total number
of packages dispensed per beneﬁ ciary, total drug expenditure. IMPLEMENTATION
STRATEGY: The MHS database was explored to identify trends in medication 
use and expenditures during the years 1998 to 2007. Expenditures were matched to 
the Israeli 2007 cost-of health living. Eight major pharmacological groups accounted
for half of the costs and were further detailed: antibiotics (representing “acute
therapy”), oncology drugs (for “severely ill”), cardiovascular, diabetic, lipid lowering
drugs and anti-depressive medications (for “chronic patients”), and medication to
treat migraine and asthma (“seasonal” therapies). RESULTS: During the study period 
MHS beneﬁ ciaries increase by 34.5% up to 1.74 million people. In this period rise of 
23% in total number of packages dispensed per beneﬁ ciary was noted. The most
noticeable rise in this parameter was noted in hypo-lipemic agents (394%), while the
most noticeable drop was noted in antibiotics (21%). In between, a rise of 84% was 
noticed on anti-neoplastic agents. During this period, 62% rise in total drug expendi-
ture (21% after correction for increased number of beneﬁ ciaries) was observed. The 
relative share of expenses of the 8 pharmacological groups was signiﬁ cantly changed,
with most noticeable rise of 454% in anti-neoplastic agents and 60% drop in antibiot-
ics. The total expenses on hypol-ipemic agents rose by 72%. LESSONS LEARNED:
The signiﬁ cant rise in medications use and expenses during the study period reﬂ ects 
changes in several parameters such as more aggressive treatment targets, better educa-
tion of physicians and patients, implementation of pre-authorization techniques and
introduction of newly developed, expensive medications. If continues, the dramatic 
rise in the share of expenses on anti-neoplastic drugs in MHS, as in other health care
givers in developed countries, could become a threat to the public health funding,
who’s budgets are limited, but in the long run could threat the drug manufacturers as
well. Discussions between health care givers, regulatory authorities and drug manu-
facturers in order to agree upon “rules of play” reﬂ ecting mutual interests are neces-
sary to resolve this threat.
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OBJECTIVES: With recent changes in ESA prescribing information and coverage
limitations, this study evaluated current epoetin alfa (EPO) and darbepoetin alfa 
(DARB) real-world utilization in cancer chemotherapy patients in two different large, 
US outpatient settings. METHODS: Medical claims from the Ingenix IMPACT 
Managed Care and PREMIER Perspective Comparative Hospital databases, between 
2006Q1–2007Q4 were analyzed. Patients were q18 years old, had q1 cancer diagno-
sis, newly initiated on EPO or DARB with q2 doses of either drug as outpatients, and
received chemotherapy during ESA treatment. Mean cumulative dose was used to 
assess impact of ESA prescribing information changes on drug utilization over time. 
The EPO : DARB dose ratio was calculated from the mean cumulative dose of EPO
and DARB. RESULTS: A total of 16,555 ESA treatment episodes (IMPACT:9,301; 
PREMIER:7,259) were identiﬁ ed. Patients receiving EPO were slightly older in 
IMPACT (EPO: 58.4 years; DARB: 56.3 years, p  0.0001) and slightly younger in 
PREMIER (EPO: 62.7 years; DARB: 64.0 years, p  0.0001), compared to DARB. A 
lower proportion of women was observed for the EPO groups (IMPACT: 64.2% vs.
68.4%; PREMIER: 62.2% vs. 65.4%, p  0.05 for both). The overall cumulative dose
per treatment episode was EPO 317,954 Units and DARB 1,238 mcg for IMPACT 
and EPO 263,582 Units and DARB 1,005 mcg for PREMIER, corresponding to
similar dose ratios of 257:1 and 262:1 for the managed care and hospital outpatient 
settings, respectively. Over time, mean treatment duration and cumulative ESA dose 
presented a downward trend for both EPO and DARB groups in both settings, with
dose ratios decreasing from 258:1 to 227:1 in IMPACT and from 279:1 to 209:1 in
PREMIER between 2006Q1 and 2007Q4. CONCLUSIONS: This study of cancer 
patients receiving chemotherapy in two outpatient settings reported decreased ESA 
utilization and EPO: DARB dose ratios following recent changes to ESA prescribing 
information and coverage.
CN2
WHEN IS CANCER CARE COST-EFFECTIVE? A SYSTEMATIC
OVERVIEW OF COST-UTILITY ANALYSES IN ONCOLOGY
Greenberg D1, Earle C2, Fang C1, Eldar-Lissai A3, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2Sunnybrook Health Sciences Centre, Toronto, ON, 
Canada, 3University of Rochester, Rochester, NY, USA
OBJECTIVES: New cancer treatments pose a substantial ﬁ nancial burden on patients,
their families, and society as a whole. Cost-utility analyses (CUAs) provide necessary 
information on the value for money and are widely published in the medical and
economic literature. We describe the growth over time of cancer-related CUAs 
and investigate whether methodological quality has improved. METHODS: We sys-
tematically searched the English-language literature for original cancer-related CUAs 
published through 2006 using Medline and other databases. Two trained readers
independently audited each study and collected data on a variety of elements related
to study origin, methods, and reporting of results. RESULTS: We identiﬁ ed 200 cancer-
related CUAs (currently included in the Tufts Medical Center Cost-Effectiveness 
Analysis Registry; www.cearegistry.org). The average annual number of studies has 
increased from 7 during 1988–2001 to 22 during 2002–2006. Leading sites studied
were breast (34%), colorectal (12%), and hematological (12%) cancers. Studies
have pertained to the U.S. (53%) U.K. (10%), The Netherlands (8%), and Canada 
(7%) and examined interventions for tertiary care (71%), secondary prevention
(22%), and primary prevention (7%). The pharmaceutical industry funded 25%
of studies, 41% were funded by non-industry sources and 32% did not disclose
any funding source. The median reported cost-effectiveness ratio (2007 values) 
was $32,000 for breast cancer, $17,000 for colorectal cancer, and $39,500 for hema-
tological cancers. Although adherence to recommended methods has somewhat 
improved in recent years, the average quality of studies (on a 1–7 Likert scale) 
was 4.2(o 1.1) and did not change substantially. CONCLUSIONS: The economic 
impact of cancer related interventions has received increased attention in the medical 
literature due to the very high cost of many newer cancer drugs. The lack of change 
in the quality of published studies suggests that journals should adopt a more rigorous
review to help ensure that authors adhere to guidelines for conducting and reporting 
CUAs.
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OBJECTIVES: This burden of illness study was conducted to assess the 12-month
resource utilization and health care costs, along with the major drivers of those 
costs, associated with an incident diagnosis of colorectal cancer (CRC). METHODS:
An analysis of incident CRC patients identiﬁ ed using a claims database, was per-
formed, for 2005, 2006, and 2007. CRC patients and the age and gender matched
comparator group (1:4) for each year, were required to have continuous enrollment 
in a plan and no CRC diagnoses during the 18 months prior to the ﬁ rst diagnosis 
of CRC in the year. The CRC and comparison groups were each described in terms 
of their health care service use and health care costs, which were compared, using
nonparametric Wilcoxon rank-sum tests, with mean values reported here for 2007. 
RESULTS: There were 13,673 patients diagnosed with CRC in 2007, in this database,
and we selected 54,688 controls. The mean health care cost for these patients 
diagnosed with CRC was $36,558 vs. $6,407 for controls; p  0.001. The primary 
drivers for this nearly 6 times greater cost difference between the 2 groups were: hos-
pitalizations ($15,996 vs. $1,959; p  0.001); prescription drugs ($6,689 vs. $1,382; 
p  0.001); radiology tests ($2,312 vs. $333; p  0.001); and physician visits ($1,665 
vs. $617; p  0.001). Resource utilization over the 12-month period showed that 
the patients with CRC, when compared to the control group, had a signiﬁ cantly
greater (p  0.001) mean number of hospitalizations (0.9 vs. 0.2); prescriptions drugs 
(33 vs. 17); radiology tests (9 vs. 2); and physician visits (12 vs. 7). The results were
similar for analyses conducted on 2006 and 2005 data. CONCLUSIONS: The signiﬁ -
cantly higher 12-month resource utilization and health care costs noted in patients
diagnosed with CRC, compared to age and gender matched controls, are primarily
driven by an increased need for hospitalizations, prescription drugs, radiology tests, 
and physician visits.
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OBJECTIVES: The trade-off between cost and mortality among stage IV colorectal 
cancer patients treated with 5FU/leucovorin/oxaliplatin (FOLFOX) or 5FU/leucovo-
rin/irinotecan (FOLFIRI) was examined. Multiple linked data sources were necessary
to obtain treatment, cancer stage, cost, and mortality. METHODS: Adults with 
colorectal cancer newly treated with FOLFOX or FOLFIRI were identiﬁ ed from a 
claims database for services January 1, 2002-December 31, 2005. Privacy board
approval for waiver of patient consent was obtained, and cancer stage was abstracted
from medical records; death was obtained from the National Death Index. Once 
matched, 41 FOLFOX and 86 FOLFIRI patients had stage IV cancer and were
retained. Costs were analyzed using generalized linear modeling; mortality was 
modeled using Cox proportional hazards analysis. Both controlled for age, gender, 
region, comorbidities, and treatment (biologic use, surgery, radiation). Sensitivity
analysis of cost was performed to adjust for availability of generic irinotecan in 2008.
Relative value of FOLFOX and FOLFIRI was measured by an incremental cost-effec-
tiveness ratio (ICER). Conﬁ dence intervals were estimated by bootstrapping with 1000 
replications. RESULTS: Unadjusted annualized mean cost was $152,213 (95% conﬁ -
dence interval [CI]: $113,547–$190,878) for FOLFOX, $107,994 (95% CI: $92,356–
$123,632) for FOLFIRI. Death occurred among 5 (12%) FOLFOX and 42 (53%) 
FOLFIRI patients. Adjusted analysis found no statistical difference in cost between 
cohorts. Cox analysis found signiﬁ cant survival advantage for FOLFOX compared to
FOLFIRI (Hazard ratio  5.2; 95% CI: 1.7–15.8). Biologic agent use was higher in 
the FOLFOX cohort and was associated with survival. ICER found one additional 
life-year saved was $1,236 (95% CI $300–$2350) with FOLFOX compared to 
